, Tracking Stock Market Picks
Enter Symbol:
Rating: MNKD
Underperform $1

Mannkind Corporation (NASDAQ: MNKD) rated to Underperform with price target $1 by RBC Capital Mkts

Wednesday,  Nov 4, 2015  8:25 AM ET by Dave Ficere

RBC Capital Mkts rated
Mannkind Corporation (NASDAQ: MNKD) to Underperform with price target $1.

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.

RBC Capital Markets is an international corporate and investment bank that provides innovative solutions and a focused set of products and services to institutions, corporations, governments and high net worth clients around the world. With nearly 3,700 professional and support staff, we operate out of 75 offices in 15 countries and deliver our products and services through operations in Asia and Australasia, the UK and Europe and in every major North American city.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy